{"id":33261,"date":"2025-05-23T00:48:13","date_gmt":"2025-05-22T22:48:13","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2025\/05\/23\/early-neutrophil-responses-are-potential-biomarkers-to-predict-severe-covid-19-in-adultsananya-singh-on-22-de-may-de-2025-at-1000\/"},"modified":"2025-05-23T00:48:13","modified_gmt":"2025-05-22T22:48:13","slug":"early-neutrophil-responses-are-potential-biomarkers-to-predict-severe-covid-19-in-adultsananya-singh-on-22-de-may-de-2025-at-1000","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2025\/05\/23\/early-neutrophil-responses-are-potential-biomarkers-to-predict-severe-covid-19-in-adultsananya-singh-on-22-de-may-de-2025-at-1000\/","title":{"rendered":"Early neutrophil responses are potential biomarkers to predict severe COVID-19 in adults\u200bAnanya Singh   on 22 de May de 2025 at 10:00"},"content":{"rendered":"<div>\n<p><b>J Leukoc Biol<\/b>. 2025 May 7;117(5):qiaf035. doi: 10.1093\/jleuko\/qiaf035.<\/p>\n<p><b>ABSTRACT<\/b><\/p>\n<p>In the early COVID-19 pandemic, the strain on healthcare facilities highlighted the need for reliable biomarkers to predict progression to severe COVID-19. Neutrophils, the most abundant leukocytes in circulation, are early defenders against pathogens. In a Singaporean adult cohort, early neutrophil mediators were assessed for their suitability as prognostic biomarkers of COVID-19 complications. Plasma levels of myeloperoxidase (MPO), elastase, soluble urokinase plasminogen activator receptor (suPAR), and soluble suppressor of tumorigenicity 2 (sST2) in 35 nonsevere and 14 severe cases were measured twice, 2 to 7 d apart after hospitalization. Nineteen controls were included. The levels of MPO, elastase, suPAR, and sST2 were significantly higher in patients with severe COVID-19 compared with those with mild and healthy controls. At baseline sampling, MPO and suPAR predicted severe COVID-19 and had AUROCs of 0.76 and 0.87, respectively. MPO and suPAR at cut-off values of 26.41 ng\/mL and 3.19 ng\/mL, respectively showed approximately 71% sensitivity and 81% to 84% specificity to differentiate severe COVID-19. In contrast, elastase and neutrophil counts were less predictive of severe disease. In adult COVID-19, MPO and suPAR may be reliable prognostic biomarkers of severe disease during acute COVID-19. Further validation of these markers in a larger cohort and in other infectious diseases is warranted.<\/p>\n<p>PMID:<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40402813\/?utm_source=WordPress&amp;utm_medium=rss&amp;utm_content=8405628&amp;ff=20250522184805&amp;v=2.18.0.post9+e462414\">40402813<\/a> | DOI:<a href=\"https:\/\/doi.org\/10.1093\/jleuko\/qiaf035\">10.1093\/jleuko\/qiaf035<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>J Leukoc Biol. 2025 May 7;117(5):qiaf035. doi: 10.1093\/jleuko\/qiaf035. ABSTRACT In the early COVID-19 pandemic, the strain on healthcare facilities highlighted the need for reliable biomarkers to predict progression to severe COVID-19. Neutrophils, the most abundant leukocytes in circulation, are early defenders against pathogens. In a Singaporean adult cohort, early neutrophil mediators were assessed for their &#8230; <a title=\"Early neutrophil responses are potential biomarkers to predict severe COVID-19 in adults\u200bAnanya Singh   on 22 de May de 2025 at 10:00\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/05\/23\/early-neutrophil-responses-are-potential-biomarkers-to-predict-severe-covid-19-in-adultsananya-singh-on-22-de-may-de-2025-at-1000\/\" aria-label=\"Read more about Early neutrophil responses are potential biomarkers to predict severe COVID-19 in adults\u200bAnanya Singh   on 22 de May de 2025 at 10:00\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[86,42],"tags":[],"class_list":["post-33261","post","type-post","status-publish","format-standard","hentry","category-journal-of-leukocyte-biology","category-publicaciones"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/33261","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=33261"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/33261\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=33261"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=33261"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=33261"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}